Market Cap 5.29B
Revenue (ttm) 3.51M
Net Income (ttm) -581.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -16,569.80%
Debt to Equity Ratio 0.00
Volume 1,733,400
Avg Vol 1,987,042
Day's Range N/A - N/A
Shares Out 96.45M
Stochastic %K 84%
Beta 1.74
Analysts Strong Sell
Price Target $80.78

Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therap...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 41 561 32 77
Address:
Baarerstrasse 14, Zug, Switzerland
handmedown1
handmedown1 May. 9 at 12:32 PM
$CRSP looks like a bear flag.....
0 · Reply
svertical1
svertical1 May. 9 at 5:20 AM
$CRSP Should be CRSP, $EDIT $NTLA https://x.com/agingroy/status/2052840682662793528?s=42&t=lVKGgcMdQmE679bIABPvLg
0 · Reply
DragonAlgoTrades
DragonAlgoTrades May. 8 at 6:43 PM
🐉 $CRSP CALL — DragonAlgo® Signal Contract: CRSP CALL Expiry: 2026-05-15 | Strike: $55.00 | Type: CALL Option Plan (premium): Entry: $1.88 Stop: $1.35 TP1: $2.44 TP2: $3.19 TP3: $4.50 Volatility regime is active. 🔗 https://dragonalgo.com
0 · Reply
DegenStock
DegenStock May. 8 at 6:34 PM
$CRSP how do you guys think this will impact the gene editing space, if at all? I know Marty was advertising a lot for gene editing process approvals and streamlining. Not sure how to read into this
0 · Reply
BULLY83
BULLY83 May. 8 at 6:10 PM
$CRSP infinite money glitch, buy at 50, sell at 57
1 · Reply
Wordtoyourmother
Wordtoyourmother May. 8 at 5:40 PM
0 · Reply
Jami_JO
Jami_JO May. 8 at 5:15 PM
0 · Reply
NMax
NMax May. 8 at 4:57 PM
$CRSP loading calls on this 😎
0 · Reply
EMPIR3_37
EMPIR3_37 May. 8 at 4:50 PM
$CRSP Strong action today and 1 buy left on the swing into $60’s. Pretty quiet around here all things considered.
0 · Reply
MorganHoratio
MorganHoratio May. 8 at 3:18 PM
The 5 stocks with realistic potential for significant upside within the next year are: 1. $JOBY - eVTOL air taxis nearing certification/commercial launch. 2. $CRSP- CRISPR gene-editing therapies with multiple late-stage catalysts. 3. $GTBIF - Cannabis if U.S. federal reform accelerates. 4. $IREN - Bitcoin mining + AI data center power play. 5. $SOFI - Fintech scaling into full digital banking. $IREN just completed its metamorphosis with a $3.4B NVIDIA contract, transitioning from a miner to an AI infra titan. $JOBY is equally exciting, having cleared its FAA SR3 audit this week—commercial launch is finally within sight. Meanwhile, $SOFI’s Q1 results ($1.1B revenue, +41%) prove its full-digital banking flywheel is in high gear. With $IREN already leading the momentum, do you stick with the proven winner, or do you hunt for the next catalyst in gene-editing with $CRSP? Which of these 5 holds the most "multi-bagger" potential for you? Let’s debate!
0 · Reply
Latest News on CRSP
Wall Street Is Completely Wrong About These 5 Stocks

Apr 9, 2026, 1:35 PM EDT - 4 weeks ago

Wall Street Is Completely Wrong About These 5 Stocks

HPQ HUT NVDA RCL


Crispr Therapeutics falls -9.2%

2026-03-10T16:05:15.000Z - 2 months ago

Crispr Therapeutics falls -9.2%


Crispr Therapeutics rumor highlighted in Betaville blog

2026-02-26T15:40:14.000Z - 2 months ago

Crispr Therapeutics rumor highlighted in Betaville blog


The Big 3: ASML, GOOGL, CRSP

Jul 15, 2025, 12:01 PM EDT - 10 months ago

The Big 3: ASML, GOOGL, CRSP

ASML GOOG GOOGL


The Big 3: CRSP, OKLO, GME

Jun 23, 2025, 12:01 PM EDT - 11 months ago

The Big 3: CRSP, OKLO, GME

OKLO GME


Final Trade: UAL, NKE, SLV & CRSP

May 24, 2024, 7:40 PM EDT - 2 years ago

Final Trade: UAL, NKE, SLV & CRSP

SLV NKE UAL


Final Trade: HPQ, RSG, GM, CRSP

Mar 1, 2024, 6:21 PM EST - 2 years ago

Final Trade: HPQ, RSG, GM, CRSP

GM HPQ RSG


FDA Approves New CRISPR Gene-Editing Treatment

Jan 16, 2024, 5:59 PM EST - 2 years ago

FDA Approves New CRISPR Gene-Editing Treatment

VRTX


handmedown1
handmedown1 May. 9 at 12:32 PM
$CRSP looks like a bear flag.....
0 · Reply
svertical1
svertical1 May. 9 at 5:20 AM
$CRSP Should be CRSP, $EDIT $NTLA https://x.com/agingroy/status/2052840682662793528?s=42&t=lVKGgcMdQmE679bIABPvLg
0 · Reply
DragonAlgoTrades
DragonAlgoTrades May. 8 at 6:43 PM
🐉 $CRSP CALL — DragonAlgo® Signal Contract: CRSP CALL Expiry: 2026-05-15 | Strike: $55.00 | Type: CALL Option Plan (premium): Entry: $1.88 Stop: $1.35 TP1: $2.44 TP2: $3.19 TP3: $4.50 Volatility regime is active. 🔗 https://dragonalgo.com
0 · Reply
DegenStock
DegenStock May. 8 at 6:34 PM
$CRSP how do you guys think this will impact the gene editing space, if at all? I know Marty was advertising a lot for gene editing process approvals and streamlining. Not sure how to read into this
0 · Reply
BULLY83
BULLY83 May. 8 at 6:10 PM
$CRSP infinite money glitch, buy at 50, sell at 57
1 · Reply
Wordtoyourmother
Wordtoyourmother May. 8 at 5:40 PM
0 · Reply
Jami_JO
Jami_JO May. 8 at 5:15 PM
0 · Reply
NMax
NMax May. 8 at 4:57 PM
$CRSP loading calls on this 😎
0 · Reply
EMPIR3_37
EMPIR3_37 May. 8 at 4:50 PM
$CRSP Strong action today and 1 buy left on the swing into $60’s. Pretty quiet around here all things considered.
0 · Reply
MorganHoratio
MorganHoratio May. 8 at 3:18 PM
The 5 stocks with realistic potential for significant upside within the next year are: 1. $JOBY - eVTOL air taxis nearing certification/commercial launch. 2. $CRSP- CRISPR gene-editing therapies with multiple late-stage catalysts. 3. $GTBIF - Cannabis if U.S. federal reform accelerates. 4. $IREN - Bitcoin mining + AI data center power play. 5. $SOFI - Fintech scaling into full digital banking. $IREN just completed its metamorphosis with a $3.4B NVIDIA contract, transitioning from a miner to an AI infra titan. $JOBY is equally exciting, having cleared its FAA SR3 audit this week—commercial launch is finally within sight. Meanwhile, $SOFI’s Q1 results ($1.1B revenue, +41%) prove its full-digital banking flywheel is in high gear. With $IREN already leading the momentum, do you stick with the proven winner, or do you hunt for the next catalyst in gene-editing with $CRSP? Which of these 5 holds the most "multi-bagger" potential for you? Let’s debate!
0 · Reply
Reverend_Bob_Dobbs
Reverend_Bob_Dobbs May. 8 at 3:08 PM
0 · Reply
NMax
NMax May. 8 at 2:31 PM
$GME $CRSP $OGEN Extreme value is waiting for the patient.See you next week. 🤑🤑🤑
0 · Reply
NMax
NMax May. 8 at 1:23 PM
$GME $CRSP $OGEN Delighted to continue averaging at these prices! 😎 Continuing to add next week!!! 🤑🤑🤑
0 · Reply
Takingtigermountain
Takingtigermountain May. 8 at 2:49 AM
$CRSP TURD EDITING
0 · Reply
Oiljunkie
Oiljunkie May. 7 at 9:49 PM
0 · Reply
Alien1980
Alien1980 May. 7 at 5:44 PM
$CRSP bulls don't wann see a closing price below 51.9 or this will selloff until at least 49.8... Price will NOT reverse unless candles start closing above 52.2
0 · Reply
4Reel
4Reel May. 7 at 5:08 PM
$CRSP hard to go up when bios are the worst performing sector today. I buy on red days. Back to 60
0 · Reply
4Reel
4Reel May. 7 at 4:45 PM
$CRSP lost all of its gains from yesterday like it never happened again
1 · Reply
Floridaorange
Floridaorange May. 7 at 2:25 PM
$HIMS I want to buy here but man bulls seem to really hate this ticker. Are the longs here strong & confident or no longer sure? Looking to park $50K. Also considering $CRSP
8 · Reply
dens214
dens214 May. 7 at 11:51 AM
$CRSP catalyst meaning= we are not really good enough or smart enough to get an FDA approval but look at this. Now send us more money.
0 · Reply
StockCaptain7
StockCaptain7 May. 7 at 10:00 AM
$GNPX Nobody Cares… Yet The chart looks ugly, the sentiment is dead, and nobody cares. That’s exactly why I’m still watching. Biotech turns when you least expect it. $SMMT $CRSP
0 · Reply
LXP
LXP May. 7 at 6:56 AM
$CRSP this company does clinical trials like big pharma (no consideration of expense) but it also seems like they run forever. I don't think we ever saw Diabetes data. They just pivoted to a different approach.
0 · Reply